Protective effect of ethyl-3-(3-dimethyl aminopropyl)urea dihydrochloride (EDU) against LPS-induced death in mice.
Evaluation of anti-adhesive gels and bioresorbable films in animal models of intra-abdominal infection has shown that a product of the cross-linking reaction between hyaluronic acid (HA) and CM-cellulose, 1-ethyl-3-(3-dimethyl aminopropyl)urea dihydrochloride (EDU), has immunomodulatory properties. The effects of EDU were evaluated by using an endotoxin-induced shock mouse model. Pre-treatment of mice with EDU (50 mg kg(-1)) in DMSO resulted in a significant reduction in mortality following injection of LPS, compared to vehicle (DMSO) pre-treatment alone. Serum levels of TNF-alpha, IL1beta and IFN-gamma in EDU-treated mice were significantly lower than those in vehicle-treated mice. Nitric oxide (NO) concentrations in the sera of mice after inoculation with LPS were significantly lower in the EDU-treated group than in the vehicle-treated group at various time-points. In contrast, EDU pre-treatment was associated with an enhanced IL10 response after LPS injection, compared to vehicle pre-treatment alone. In vitro studies revealed that IL10 production by RAW 264.7 macrophages, elicited by LPS, was increased significantly when EDU was added to the culture medium. These results suggest that the protective effect of EDU during LPS-induced shock in mice is the result of inhibition of proinflammatory cytokines and NO production and an enhanced IL10 response.
Matsumoto
Tetsuya
T
Channing Laboratory, Department of Pathology1 and Gastroenterology Division2, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 3Laboratory of Pediatrics, Department of Pediatric Gastroenterology, Erasmus MC, Rotterdam, the Netherlands 4Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
Nieuwenhuis
Edward E S
EES
Channing Laboratory, Department of Pathology1 and Gastroenterology Division2, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 3Laboratory of Pediatrics, Department of Pediatric Gastroenterology, Erasmus MC, Rotterdam, the Netherlands 4Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
Cisneros
Ronald L
RL
Channing Laboratory, Department of Pathology1 and Gastroenterology Division2, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 3Laboratory of Pediatrics, Department of Pediatric Gastroenterology, Erasmus MC, Rotterdam, the Netherlands 4Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
Ruiz-Perez
Begoña
B
Channing Laboratory, Department of Pathology1 and Gastroenterology Division2, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 3Laboratory of Pediatrics, Department of Pediatric Gastroenterology, Erasmus MC, Rotterdam, the Netherlands 4Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
Yamaguchi
Keizo
K
Channing Laboratory, Department of Pathology1 and Gastroenterology Division2, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 3Laboratory of Pediatrics, Department of Pediatric Gastroenterology, Erasmus MC, Rotterdam, the Netherlands 4Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
Blumberg
Richard S
RS
Channing Laboratory, Department of Pathology1 and Gastroenterology Division2, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 3Laboratory of Pediatrics, Department of Pediatric Gastroenterology, Erasmus MC, Rotterdam, the Netherlands 4Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
Onderdonk
Andrew B
AB
Channing Laboratory, Department of Pathology1 and Gastroenterology Division2, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 3Laboratory of Pediatrics, Department of Pediatric Gastroenterology, Erasmus MC, Rotterdam, the Netherlands 4Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
D000818:Animals; D002460:Cell Line; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D004926:Escherichia coli / Q000378:metabolism; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000633:toxicity*; D008264:Macrophages / Q000276:immunology; D008297:Male; D051379:Mice; D009569:Nitric Oxide / Q000096:biosynthesis; D012772:Shock, Septic / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D014508:Urea / Q000031:analogs & derivatives / Q000627:therapeutic use*
C477080:1-(3-dimethylaminopropyl)-3-ethylurea; D016207:Cytokines; D008070:Lipopolysaccharides; D016753:Interleukin-10; D009569:Nitric Oxide; D014508:Urea